Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

Pfizer Ends Obesity Drug Trial After Liver Risk Emerges

Daniel Kim Views  

Shutterstock
Shutterstock

Pfizer has recently announced its decision to halt the development of danuglipron (PF-06882961), a candidate drug for obesity treatment.

Previously, Pfizer had discontinued a twice-daily oral obesity medication due to frequent nausea and vomiting side effects, which led to widespread patient discontinuation at the end of 2023. Since then, the company has been exploring various dosages of a once-daily version.

In a dose-optimization study involving 1,400 participants, Pfizer reported that danuglipron displayed liver enzyme elevations comparable to those seen with existing approved obesity drugs. However, one patient experienced liver damage.

This patient developed drug-induced liver injury but recovered after stopping danuglipron.

After thoroughly reviewing all clinical data related to danuglipron, Pfizer decided to terminate its development.

The company plans to present findings from the danuglipron clinical program at upcoming scientific conferences or academic journals. Pfizer will continue developing other oral obesity drug candidates that target the GIPR hormone.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LATEST] Latest Stories

  • Not Just Old Age: The Pneumonia That Affected Pope Francis’ Final Years
  • China Just Cranked U.S. Tariffs to 84% — And That’s Not the End of It
  • BMW's Next-Gen EV: The Bold New i3 Touring Concept Revealed
  • LEGO Technic Ferrari SF-24 F1 Car: A 1,361-Piece Tribute to Ferrari’s 2024 F1 Season
  • Hyundai’s Ioniq 6 Just Took the Top Spot in J.D. Power’s EV Ownership Study
  • Jeep’s Recon: The Next-Gen 600HP Electric SUV Ready to Tackle the Market

You May Also Like

  • 1
    Sitting Too Much Could Kill You, Even After a Heart Scare, Study Says

    LIFESTYLE 

  • 2
    Oral Probiotics Are Trending — But Are They the Real Deal?

    LIFESTYLE 

  • 3
    Love Carbs? This Simple Trick Makes Rice and Pasta Healthier

    LIFESTYLE 

  • 4
    Heart Disease Is the World’s #1 Killer—Here’s How to Protect Yourself

    LIFESTYLE 

  • 5
    Dark Spots on Your Fingers? Here’s What They Could Really Mean

    LIFESTYLE 

Popular Now

  • 1
    Rise in Early Puberty Among Girls Raises Red Flags for Parents

    LIFESTYLE&nbsp

  • 2
    How Many Times Can You REALLY Reuse a Towel? The Answer May Gross You Out

    LIFESTYLE&nbsp

  • 3
    Struggling to Wake Up? It’s Not Laziness—It’s Science

    LIFESTYLE&nbsp

  • 4
    Stevia vs. Agave: Which Sweetener Is Actually Better for You?

    LIFESTYLE&nbsp

  • 5
    Clocking 52+ Hours a Week? Your Brain May Be Paying the Price

    LIFESTYLE&nbsp

Must-Reads

  • 1
    Sitting Too Much Could Kill You, Even After a Heart Scare, Study Says

    LIFESTYLE 

  • 2
    Oral Probiotics Are Trending — But Are They the Real Deal?

    LIFESTYLE 

  • 3
    Love Carbs? This Simple Trick Makes Rice and Pasta Healthier

    LIFESTYLE 

  • 4
    Heart Disease Is the World’s #1 Killer—Here’s How to Protect Yourself

    LIFESTYLE 

  • 5
    Dark Spots on Your Fingers? Here’s What They Could Really Mean

    LIFESTYLE 

Popular Now

  • 1
    Rise in Early Puberty Among Girls Raises Red Flags for Parents

    LIFESTYLE 

  • 2
    How Many Times Can You REALLY Reuse a Towel? The Answer May Gross You Out

    LIFESTYLE 

  • 3
    Struggling to Wake Up? It’s Not Laziness—It’s Science

    LIFESTYLE 

  • 4
    Stevia vs. Agave: Which Sweetener Is Actually Better for You?

    LIFESTYLE 

  • 5
    Clocking 52+ Hours a Week? Your Brain May Be Paying the Price

    LIFESTYLE